Fidelity Investments’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-1,146,049
Closed -$123M 5654
2023
Q1
$123M Buy
1,146,049
+391,329
+52% +$45M 0.01% 916
2022
Q4
$83M Buy
754,720
+337,481
+81% +$21.9M 0.01% 1043
2022
Q3
$24.6M Buy
417,239
+64,054
+18% +$2.93M ﹤0.01% 1546
2022
Q2
$9.97M Buy
353,185
+51,488
+17% +$1.49M ﹤0.01% 1969
2022
Q1
$11.4M Buy
301,697
+497
+0.2% +$19.6K ﹤0.01% 2058
2021
Q4
$11.9M Hold
301,200
﹤0.01% 2043
2021
Q3
$7.14M Sell
301,200
-111,600
-27% -$2.63M ﹤0.01% 2253
2021
Q2
$10.1M Sell
412,800
-143,400
-26% -$3.2M ﹤0.01% 2101
2021
Q1
$10.2M Buy
+556,200
New +$11.5M ﹤0.01% 2030

Other funds holding RXDX

Fidelity Investments's RXDX Position: Q2 2023 in Review

Fidelity Investments sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 1,146,049 shares — an estimated $123M sold.

Fidelity Investments first reported a position in RXDX in Q1 2021 and held it in 9 quarters. The position peaked at $123M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

  • Fidelity Investments reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Fidelity Investments sold 1,146,049 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $123M.
  • Fidelity Investments first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
  • Fidelity Investments's Prometheus Biosciences, Inc. Common Stock position peaked at $123M in Q1 2023.
  • 2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Fidelity Investments's 13F filing for Q2 2023, filed 11 Aug 2023.